Industry news

• Pharma, Biotech and Medtech 2018 in Review

  04 March 2019 Evaluate

  The Vantage 2018 in Review paints a mixed picture for biopharma and medtech in 2018. Key indicators on share price and dealmaking showed weakness, but there are signs of health from the industry in IPO outcomes, venture financing activity, and FDA drug approvals.

• Bladder Cancer Surgery Research of Russian and European Scientists

  01 March 2019 GMP News

  The Medical University of Vienna (Austria), Asclepius Сlinic (Hamburg, Germany) and the University of Turin (Italy) have also joined the project. The research centers will study on and compare transurethral resection of bladder tumors with laser en bloc resection.

• FDA Answers about Safety of Generics

  01 March 2019 GMP News

  In a statement, FDA Commissioner Scott Gottlieb laid out the case for the safety and effectiveness of generic drugs compared to brand drugs. In response to news reports that questioned the safety and effectiveness of generic drugs compared with brand drugs FDA Commissioner Scott Gottlieb, MD, and Center for Drug Evaluation and Research Director Janet Woodcock, MD, issued a statement on Feb. 22, 2019 detailing the steps the agency goes through to ensure that generic drugs are safe and effective.

• Russian Meds Arrived to Venezuela

  28 February 2019 GMP News

  Venezuelan President Nicolas Maduro thanked Russian President Vladimir Putin and the Pan American Health Organization (PAHO) for the supplies of medicines to the crisis-torn country.

• Big Pharma Answered for High Prices

  28 February 2019 GMP News

  U.S. senators called drug pricing practices “morally repugnant” and told drug company executives they do not want to hear them blame others for the high prices, taking an aggressive stance at a Senate hearing on the rising costs of prescription medicines.

• FDA Reacts to Generic Drug Critics

  26 February 2019 BioPharm International

  In response to news reports that questioned the safety and effectiveness of generic drugs compared with brand drugs, FDA Commissioner Scott Gottlieb, MD, and Center for Drug Evaluation and Research Director Janet Woodcock, MD, issued a statement on Feb. 22, 2019 detailing the steps the agency goes through to ensure that generic drugs are safe and effective.

• FDA drafts ‘leapfrog’ guidance on brain-computer interface tech

  26 February 2019 Conor Hale / FierceBiotech

  The FDA is hoping to help the industry take a leap toward what was once pure science fiction: interfaces that link brains and computers, allowing a person to directly control devices with their thoughts.

• Russian Inspectorate Urges to Implement Different GPs

  25 February 2019 GMP News

  The innovative breakthrough is only possible provided there is close cooperation between patients, regulators, scientists and the industry. Such a statement laid down the basis of the 14th international conference «Pharmaceutical Business in Russia».

• Med Pricing Pushes People into Poverty

  25 February 2019 GMP News

  Spending on health is growing faster than the rest of the global economy, accounting for 10% of global gross domestic product (GDP). A new report on global health expenditure from the World Health Organization (WHO) reveals a swift upward trajectory of global health spending, which is particularly noticeable in low- and middle-income countries where health spending is growing on average 6% annually compared with 4% in high-income countries.

• Sales of generic oncology drugs surge

  22 February 2019 European Pharmaceutical Review

  A recent study has suggested that there has been a significant increase in spending on cancer management and treatment drug development. More than one-third of the trials proposed by manufacturers are aimed at offering personalised cancer treatments, which further propels the demand for generic oncology drugs. A host of these factors have contributed massively to the expansion of the generic oncology drugs market at the global level.